TY - JOUR T1 - COVID-19 Drug Development. A1 - Kim,Seungtaek, PY - 2021/10/19/received PY - 2021/11/23/revised PY - 2021/11/29/accepted PY - 2021/12/7/pubmed PY - 2022/2/9/medline PY - 2021/12/6/entrez KW - COVID-19 KW - SARS-CoV-2 KW - convalescent plasma KW - drug repurposing KW - monoclonal antibody SP - 1 EP - 5 JF - Journal of microbiology and biotechnology JO - J Microbiol Biotechnol VL - 32 IS - 1 N2 - Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges. SN - 1738-8872 UR - https://www.unboundmedicine.com/medline/citation/34866128/COVID_19_Drug_Development_ DB - PRIME DP - Unbound Medicine ER -